AbbVie announced it will acquire Apogee Therapeutics in a deal valued at approximately $10.9 billion. Apogee's lead assets are long-acting antibody candidates targeting IL-13, IL-4Rα, and OX40L for atopic dermatitis and asthma — diseases where AbbVie already competes with Rinvoq and Skyrizi, making the pipeline strategically coherent. The acquisition is one of AbbVie's largest since the $63B Allergan deal and underscores its urgency to build durable revenue as Humira biosimilar pressure continues.

The near-term setup for ABBV is classic large-cap acquirer: the stock typically sells off on deal announcement as the market prices in acquisition risk and EPS dilution — AbbVie already carries thin reported net margins (~6.9%) and $2.36 diluted EPS on a $61.2B revenue base. Apogee's pipeline is early-stage, so the key watch items are Phase 2/3 readouts, deal close timing, and whether AbbVie issues guidance updates reflecting deal financing costs. The acquirer discount is the tradeable tension here.